Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Harvard Business School
AstraZeneca
Medtronic
Boehringer Ingelheim

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR GLYBURIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Glyburide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00035542 ↗ A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes. Completed Bristol-Myers Squibb Phase 3 2001-12-01 The purpose of this clinical research study is to see if Glucovance, a medication currently approved for use in adults with type 2 diabetes, can control type 2 diabetes safely and effectively in children 9 to 16 years of age.
NCT00035568 ↗ A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes Completed Bristol-Myers Squibb Phase 4 2002-02-01 The purpose of this clinical research study is to support earlier observations that Glucovance controls glucose levels after a mean, and improves overall glucose control better than metformin or glyburide therapy alone in adults with type 2 diabetes.
NCT00046462 ↗ Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment Completed Sanofi Phase 3 2001-11-01 The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination.
NCT00123643 ↗ Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients Completed GlaxoSmithKline Phase 4 2003-05-01 The purpose of this study is to compare the vascular effects of two commonly used diabetes medications, rosiglitazone and glyburide in type 2 diabetic patients.
NCT00123643 ↗ Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients Completed St. Paul Heart Clinic Phase 4 2003-05-01 The purpose of this study is to compare the vascular effects of two commonly used diabetes medications, rosiglitazone and glyburide in type 2 diabetic patients.
NCT00160485 ↗ Glyburide Compared to Insulin in the Management of White's Classification A2 Gestational Diabetes Withdrawn Tripler Army Medical Center Phase 4 2004-06-01 The purpose of this study is to determine whether the oral administration of glyburide is as effective as insulin in the treatment of gestational diabetes. 1. SYNOPSIS: Infants born to mothers with gestational diabetes(GDM) are at risk for a variety of adverse perinatal outcomes including macrosomia with subsequent birth trauma and cesarean delivery, neonatal hypoglycemia, polycythemia, jaundice, hypocalcemia, respiratory depression and newborn intensive care unit admission. These adverse outcomes are thought to be related to the degree of maternal hyperglycemia during pregnancy. Women with GDM are typically treated with insulin to lower blood glucose levels to as near-normal as possible. A single randomized trial has suggested that the oral sulfonylurea, glyburide is a clinically effective and safe alternative to insulin therapy. 2. Many obstetric care providers have adopted the use of glyburide in the routine management of gestational diabetes. The American College of Obstetrics and Gynecology and the American Diabetic Association both state that further studies are needed in a larger patient population before the use of newer oral hypoglycemic agents can be supported for use in pregnancy. 3. STATUS: Previous studies have demonstrated that there is no maternal-fetal transfer of glyburide and when compared to insulin is an effective alternative to insulin. Additionally, a published cost analysis concluded that glyburide is significantly less costly than insulin for the treatment of GDM. The benefits of an oral agent for the management of gestational diabetes include less discomfort for the patient in drug administration, lower requirement for patient education in the administration of injectable medications and less chance of error in dosing. Our study population is more ethnically diverse and our incidence of large for gestational age infants is lower than in the largely Hispanic population studied by Langer et al. Many obstetricians, including ourselves, apply different criteria than Langer for diagnosing gestational diabetes , and for deciding when to institute insulin therapy. It is our goal to confirm the prior single study concerning the safety and efficacy of glyburide in reducing the complications of GDM utilizing a more ethnically diverse population with more realistic goals in glycemic control. To this end we will add to the medical literature supporting this alternative therapy to insulin.
NCT00162175 ↗ PPAR-COMBO With Sulfonylurea Completed Bristol-Myers Squibb Phase 3 2003-07-01 A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Glyburide Therapy in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Glyburide

Condition Name

Condition Name for Glyburide
Intervention Trials
Gestational Diabetes 10
Healthy 10
Diabetes Mellitus, Type 2 8
Diabetes Mellitus 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Glyburide
Intervention Trials
Diabetes Mellitus 41
Diabetes Mellitus, Type 2 23
Diabetes, Gestational 16
Edema 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Glyburide

Trials by Country

Trials by Country for Glyburide
Location Trials
United States 303
United Kingdom 48
Japan 48
China 36
Germany 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Glyburide
Location Trials
Texas 18
Pennsylvania 15
California 13
Maryland 12
Illinois 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Glyburide

Clinical Trial Phase

Clinical Trial Phase for Glyburide
Clinical Trial Phase Trials
Phase 4 19
Phase 3 17
Phase 2 5
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Glyburide
Clinical Trial Phase Trials
Completed 48
Terminated 8
Unknown status 6
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Glyburide

Sponsor Name

Sponsor Name for Glyburide
Sponsor Trials
GlaxoSmithKline 8
Biogen 6
Takeda 5
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Glyburide
Sponsor Trials
Other 53
Industry 50
U.S. Fed 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
McKesson
Express Scripts
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.